NY-ESTÉE-LAUDER/IU
Estée Lauder today announced that it has signed acclaimed Korean singer, songwriter and actress, IU, as its newest Global Brand Ambassador. IU will be Estée Lauder’s first Korean Global Brand Ambassador and will be featured in campaigns for the brand’s hero franchises, Advanced Night Repair and Double Wear. IU’s first campaign will debut in April 2024. IU joins the current roster of Estée Lauder Global Ambassadors, including Ana de Armas, Amanda Gorman, Bianca Brandolini D’Adda, Carolyn Murphy, Grace Elizabeth, Imaan Hammam, Karlie Kloss, Manushi Chhillar and Yang Mi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411412295/en/
Estée Lauder Signs Korean Singer and Actress IU as New Global Brand Ambassador (Photo: Business Wire)
“We are thrilled to welcome IU as Estée Lauder’s newest Global Brand Ambassador,” said Justin Boxford, Global Brand President, Estée Lauder. “IU is one of the most influential artists of her time. She has been able to connect with her fans around the world in such a deep and meaningful way through her music and her extraordinary social media presence. We’re excited to collaborate with such a talented and inspiring artist whose relevancy and far-reaching popularity will allow us to connect with a new generation of consumers in Asia and around the world.”
“I am incredibly excited to be joining Estée Lauder,” said IU. “It is an iconic brand founded by an inspirational woman leader and is beloved by so many women around the world. I am truly honored to be part of it.”
“Over the past 16 years, IU has been a pioneer in every aspect of her career, inspiring fans around the world with her talent, passion, and dedication. Beyond her star power, it’s her sense of purpose and commitment to giving back to others that deeply connects with our brand’s core values,” said Kyumoon Lee, Senior Vice President/General Manager, Estée Lauder Asia Pacific.
About IU
IU is a South Korean singer, songwriter, actress, and philanthropist. With a career of more than 16 years, IU is one of the most popular and beloved artists in Korea and across Asia. To date, she has released 6 studio albums, 9 EP’s, and has debuted over 30 singles including drama O.S.Ts. She is also known worldwide for her acting in TV dramas and movies, including Broker, Hotel del Luna, My Mister, and more. As a multi-talented artist, IU has inspired fans across generations with her lyrics, voice and authenticity. She also has made unwavering commitments to charity, dedicating herself to various philanthropic causes and inspiring other artists in the industry to follow suit. As of February 2024, IU has released a new album, The Winning, and has embarked on her first world tour across Asia, Europe and North America.
About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating the most innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with consumers in over 150 countries around the world and at dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic point of view.
NYSE: EL
ELC-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411412295/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom